Tech Company Financing Transactions
Selexagen Therapeutics Funding Round
On 9/30/2011, Selexagen Therapeutics secured $100 thousand in funding from Windamere Venture Partners.
Transaction Overview
Company Name
Announced On
9/30/2011
Transaction Type
Venture Equity
Amount
$100,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
4653 Carmel Mountain Rd. 308-300
San Diego, CA 92130
USA
San Diego, CA 92130
USA
Phone
Website
Email Address
Overview
Utilizing molecular modeling and structure based drug design technologies, Selexagen designs excellent drug-like chemical libraries from which development candidates are rapidly evolved and positioned for clinical trials in cancer patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Randall Woods
Chief Executive Officer
Lauren Otsuki
Chief Scientific Officer
Patrick O'Connor
Founder
Scott Glenn
Founder
David Matthews
Founder
Jean-Michel Vernier
Browse more venture capital transactions:
Prev: 9/30/2011: CoAlign Innovations venture capital transaction
Next: 9/30/2011: Aureon Biosciences venture capital transaction
Share this article
News on VC Transactions
We record every notable VC transaction. VC investment data records on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs